Smoothelin-B is not a target of matrix metalloproteinase (MMP)-2 in the vasculature of endotoxemic rats

Canadian Journal of Physiology and Pharmacology

Volumn 92, Issue 10, 2014, Pages 887-891

  de Souza, Priscila ^a,b   de Castro, Michele Mazzaron ^b   Goobie, Gillian ^b   da Silva Santos, Jose Eduardo ^c   Schulz, Richard ^b  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b UNIVERSITY OF ALBERTA   (Canada)

^c FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Aorta; Calponin 1; Hypocontractility; Lipopolysaccharide; Matrix metalloproteinase inhibitor; Peroxynitrite; Protease; Sepsis

Indexed keywords

5 ETHOXYMETHOXY N HYDROXY 2 METHYL 4 (4 PHENOXYBENZAMIDO)PENTANAMIDE; CALPONIN; GELATINASE A; LIPOPOLYSACCHARIDE; NITRIC OXIDE; SMOOTHELIN; SMOOTHELIN B; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; CALCIUM BINDING PROTEIN; CYTOSKELETON PROTEIN; MUSCLE PROTEIN; SMTN PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL TONE; ENDOTOXEMIA; MALE; MUSCLE CONTRACTION; NONHUMAN; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; RAT; VASCULARIZATION; ANIMAL; COMPUTER SIMULATION; DRUG EFFECTS; HUMAN; METABOLISM; MUSCLE ISOMETRIC CONTRACTION; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; THORACIC AORTA; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTA, THORACIC; CALCIUM-BINDING PROTEINS; COMPUTER SIMULATION; CYTOSKELETAL PROTEINS; ENDOTOXEMIA; HUMANS; ISOMETRIC CONTRACTION; LIPOPOLYSACCHARIDES; MALE; MATRIX METALLOPROTEINASE 2; MICROFILAMENT PROTEINS; MUSCLE PROTEINS; MUSCLE, SMOOTH, VASCULAR; RATS, SPRAGUE-DAWLEY;

EID: 84907510500     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/cjpp-2014-0257     Document Type: Article

References (24)

1. Ali, M.A., Chow, A.K., Kandasamy, A.D., Fan, X., West, L.J., Crawford, B.D., et al. 2012. Mechanisms of cytosolic targeting of matrix metalloproteinase-2. J. Cell. Physiol. 227(10): 3397-3404. doi:10.1002/jcp.24040. PMID:22212960.
2. Castro, M.M., Cena, J., Cho, W.J., Walsh, M.P., and Schulz, R. 2012. Matrix metalloproteinase-2 proteolysis of calponin-1 contributes to vascular hypocontractility in endotoxemic rats. Arterioscler. Thromb. Vasc. Biol. 32(3): 662-668. doi:10.1161/ATVBAHA.111.242685. PMID:22199370.
3. Cauwe, B., and Opdenakker, G. 2010. Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases. Crit. Rev. Biochem. Mol. Biol. 45: 351-423. doi:10.3109/10409238. 2010.501783. PMID:20812779.
4. CCAC (Canadian Council on Animal Care). 1993. Guide to the care and use of experimental animals, 2nd ed. CCAC, Ottawa, Ont.
5. Cena, J.J., Lalu, M.M., Cho, W.J., Chow, A.K., Bagdan, M.L., Daniel, E.E., et al. 2010. Inhibition of matrix metalloproteinase activity in vivo protects against vascular hyporeactivity in endotoxemia. Am. J. Physiol. Heart Circ. Physiol. 298: H45-H51. doi:10.1152/ajpheart.00273.2009. PMID:19837953.
6. Chow, A.K., Cena, J., and Schulz, R. 2007. Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Br. J. Pharmacol. 152(2): 189-205. doi:10.1038/sj.bjp.0707344. PMID:17592511.
7. Golub, L.M., Ciancio, S., Ramamamurthy, N.S., Leung, M., and McNamara, T.F. 1990. Low-dose doxycycline therapy: effect on gingival and crevicular fluid collagenase activity in humans. J. Periodontal Res. 25(6): 321-330. doi:10.1111/ j.1600-0765.1990.tb00923.x. PMID:2177499.
8. Gurung, P., Rai, D., Condotta, S.A., Babcock, J.C., Badovinac, V.P., and Griffith, T.S. 2011. Immune unresponsiveness to secondary heterologous bacterial infection after sepsis induction is TRAIL dependent. J. Immunol. 187: 2148-2154. doi:10.4049/jimmunol.1101180. PMID:21788440.
9. Hariya, A., Takazawa, K., Yamamoto, T., and Amano, A. 2004. ONO-4817, a novel matrix metalloproteinase inhibitor, attenuates allograft vasculopathy in a rat cardiac transplant. J. Heart Lung Transplant. 23(10): 1163-1169. doi:10.1016/ j.healun.2003.08.022. PMID:15477110.
10. Hernandez, G., Bruhn, A., and Ince, C. 2013. Microcirculation in sepsis: new perspectives. Curr. Vasc. Pharmacol. 11: 161-169. doi:10.2174/1570161111311020006. PMID:23506495.
11. Hoffmann, U., Bertsch, T., Dvortsak, E., Liebetrau, C., Lang, S., Liebe, V., et al. (2006). Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis. Scand. J. Infect. Dis. 38(10): 867-872. PMID:17008230.
12. Lalu, M.M., Gao, C.Q., and Schulz, R. 2003. Matrix metalloproteinase inhibitors attenuate endotoxemia induced cardiac dysfunction: a potential role for MMP-9. Mol. Cell. Biochem. 251(1-2): 61-66. doi:10.1023/A:1025417529167. PMID:14575305.
13. Lalu, M.M., Csont, T., and Schulz, R. 2004. Matrix metalloproteinase activities are altered in the heart and plasma during endotoxemia. Crit. Care Med. 32(6): 1332-1337. doi:10.1097/01.CCM.0000127778.16609.EC. PMID:15187516.
14. Lalu, M.M., Cena, J., Chowdhury, R., Lam, A., and Schulz, R. 2006. Matrix metalloproteinases contribute to endotoxin and interleukin-1beta induced vascular dysfunction. Br. J. Pharmacol. 149(1): 31-42. doi:10.1038/sj.bjp.0706823. PMID:16880766.
15. Niessen, P., Clement, S., and Fontao, L. 2004. Biochemical evidence for interaction between smoothelin and filamentous actin. Exp. Cell Res. 292: 170-178. doi:10.1016/j.yexcr.2003.09.005. PMID:14720516.
16. Quensel, C., Krämer, J., Cardoso, M.C., and Leonhardt, H. 2002. Smoothelin contains a novel actin cytoskeleton localization sequence with similarity to troponin T. J. Cell. Biochem. 85: 403-409. doi:10.1002/jcb.10143. PMID: 11948695.
17. Rensen, S.S., Niessen, P.M., van Deursen, J.M., Janssen, B.J., Heijman, E., Hermeling, E., et al. 2008. Smoothelin-B deficiency results in reduced arterial contractility, hypertension, and cardiac hypertrophy in mice. Circulation, 118(8): 828-836. doi:10.1161/CIRCULATIONAHA.107.743690. PMID:18678771.
18. Szabó, C., Mitchell, J.A., Thiemermann, C., and Vane, J.R. 1993. Nitric oxidemediated hyporeactivity to noradrenaline precedes the induction of nitric oxide synthase in endotoxin shock. Br. J. Pharmacol. 108: 786-792. doi:10. 1111/j.1476-5381.1993.tb12879.x. PMID:7682137.
19. Szabó, C., Cuzzocrea, S., Zingarelli, B., O’Connor, M., and Salzman, A.L. 1997. Endothelial dysfunction in a rat model of endotoxic shock. Importance of the activation of poly (ADP-ribose) synthetase by peroxynitrite. J. Clin. Invest. 100(3): 723-735. doi:10.1172/JCI119585. PMID:9239421.
20. Takahashi, K., Hiwada, K., and Kokubu, T. 1988. Vascular smooth muscle calponin. A novel troponin T-like protein. Hypertension, 11: 620-626. doi:10. 1161/01.HYP.11.6.620. PMID:2455687.
21. van der Loop, F.T., Schaart, G., Timmer, E.D., Ramaekers, F.C., and Van Eys, G.J. 1996. Smoothelin, a novel cytoskeletal protein specific for smooth muscle cells. J. Cell Biol. 134: 401-411. doi:10.1083/jcb.134.2.401. PMID:8707825.
22. Vanlaere, I., and Libert, C. 2009. Matrix metalloproteinases as drug targets in infections caused by gram-negative bacteria and in septic shock. Clin. Microbiol. Rev. 22: 224-239. doi:10.1128/CMR.00047-08. PMID:19366913.
23. Viappiani, S., Nicolescu, A.C., Holt, A., Sawicki, G., Crawford, B.D., León, H., et al. 2009. Activation and modulation of 72 kDa matrix metalloproteinase-2 by peroxynitrite and glutathione. Biochem. Pharmacol. 77(5): 826-834. doi:10. 1016/j.bcp.2008.11.004. PMID:19046943.
24. Wang, W., Schulze, C.J., Suarez-Pinzon, W.L., Dyck, J.R., Sawicki, G., and Schulz, R. 2002. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation, 106: 1543-1549. doi:10.1161/01.CIR.0000028818.33488.7B. PMID:12234962.